Advertisement

Comprehensive Assessment of Curcumin as a Functional Food

  • Aditi Jain
  • Sharad Saxena
  • Vibha Rani
Chapter

Abstract

The importance of bioactive compounds present in natural sources has withdrawn ample attention in human nutrition and established as “functional food” in the field of food chemistry and as “preventive medicine” in the field of pharmacology and healthcare. Curcumin is one such promising and well-studied natural bioactive plant compound that is present in Curcuma longa and known for providing various protective effects in different diseased states. This chapter highlights the present understanding of various protective effects of curcumin in wide range of diseases including cancer, cardiovascular diseases, diabetes, obesity, Alzheimer’s disease, etc. The major emphasis is on the molecular pathways associated with curcumin-mediated effects. The significance of its unique structure attributing to its function and present advances in curcumin applications to overcome its limitations has also been discussed in detail.

Keywords

Curcumin Functional food Anticancer Antioxidant Diabetes Cardiomyopathy 

Notes

Acknowledgment

We acknowledge the Jaypee Institute of Information Technology for providing the infrastructure and literature support for conducting the detailed study presented in the chapter.

References

  1. 1.
    Agarwal NB, Jain S, Nagpal D et al (2013) Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice. Fundam Clin Pharmacol 27(2):169–172CrossRefGoogle Scholar
  2. 2.
    Anand P, Thomas SG, Kunnumakkara AB et al (2008) Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol 76:1590–1611CrossRefGoogle Scholar
  3. 3.
    Baker RG, Hayden MS, Ghosh S (2011) NF-κB, inflammation and metabolic disease. Cell Metab 13(1):11–22CrossRefGoogle Scholar
  4. 4.
    Bhandarkar SS, Arbiser JL (2007) Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol 595:185–195CrossRefGoogle Scholar
  5. 5.
    Balunas MJ, Kinghorn AD (2005) Drug discovery from medicinal plants. Life Sci 78:431–441CrossRefGoogle Scholar
  6. 6.
    Bisht S, Feldmann G, Soni S et al (2007) Polymeric nanoparticle encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnol 5:3CrossRefGoogle Scholar
  7. 7.
    Borkar N, Andersson DR, Yang M et al (2017) Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson’s disease rat model. J Pharm Pharmacol 69(9):1110–1115CrossRefGoogle Scholar
  8. 8.
    Bradford PG (2013) Curcumin and obesity. Biofactors 39(1):78–87CrossRefGoogle Scholar
  9. 9.
    Chang MT, Tsai TR, Lee CY et al (2013) Elevating bioavailability of curcumin via encapsulation with a novel formulation of artificial oil bodies. J Agric Food Chem 61:9666–9671PubMedGoogle Scholar
  10. 10.
    Cheng AL, Hsu CH, Lin JK et al (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 21:2895–2900PubMedGoogle Scholar
  11. 11.
    Chendil D, Ranga RS, Meigooni D et al (2004) Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23:1599–1607CrossRefGoogle Scholar
  12. 12.
    Choudhuri T, Pal S, Das T et al (2005) Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280:20059–20068CrossRefGoogle Scholar
  13. 13.
    Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R et al (2012) Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35(11):2121–2127CrossRefGoogle Scholar
  14. 14.
    Chuengsamarn S, Rattanamongkolgul S, Phonrat B et al (2014) Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem 25(2):144–150CrossRefGoogle Scholar
  15. 15.
    Farajzadeh R, Pilehvar-Soltanahmadi Y, Dadashpour M et al (2017) Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells. Artif Cells Nanomed Biotechnol 5:1–9CrossRefGoogle Scholar
  16. 16.
    Farhangkhoee H, Khan ZA, Mukherjee S et al (2003) Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 35(12):1439–1448CrossRefGoogle Scholar
  17. 17.
    Farhangkhoee H, Khan ZA, Chen S et al (2006) Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr Metab (Lond) 3:27CrossRefGoogle Scholar
  18. 18.
    Fleenor BS, Sindler AL, Marvi NK et al (2013) Curcumin ameliorates arterial dysfunction and oxidative stress with aging. Exp Gerontol 48:269–276CrossRefGoogle Scholar
  19. 19.
    Gao Y, Li Z, Sun M (2011) Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv 18(2):131–142CrossRefGoogle Scholar
  20. 20.
    Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787–809CrossRefGoogle Scholar
  21. 21.
    Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15:195–218CrossRefGoogle Scholar
  22. 22.
    Gurib-Fakim A (2006) Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Asp Med 27:1–93CrossRefGoogle Scholar
  23. 23.
    Hajavi J, Abbas-Momtazi A, Johnston TP et al (2017) Curcumin: a naturally occurring modulator of adipokines in diabetes. J Cell Biochem.  https://doi.org/10.1002/jcb.26121 CrossRefGoogle Scholar
  24. 24.
    Hasan M, Belhaj N, Benachour H et al (2014) Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation. Int J Pharm 461(1–2):519–528CrossRefGoogle Scholar
  25. 25.
    Hatcher H, Planalp R, Cho J et al (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631–1652CrossRefGoogle Scholar
  26. 26.
    Heger M, van Golen RF, Broekgaarden M et al (2014) The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev 66:222–307CrossRefGoogle Scholar
  27. 27.
    Helson L (2013) Curcumin (diferuloylmethane) delivery methods: a review. Biofactors 39:21–26CrossRefGoogle Scholar
  28. 28.
    Hong JH, Ahn KS, Bae E et al (2006) The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 9:147–152CrossRefGoogle Scholar
  29. 29.
    Ismail NA, Ragab S, Abd El Baky ANE et al (2014) Effect of oral curcumin administration on insulin resistance, serum resistin and fetuin-A in obese children: randomized placebo-controlled study. RJPBCS 5:887–896Google Scholar
  30. 30.
    Ismail NA, Abd El Dayem SM, Salama E et al (2016) Impact of curcumin intake on gluco-insulin homeostasis, leptin and adiponectin in obese subjects. RJPBCS 7:1891–1897Google Scholar
  31. 31.
    Jagetia GC, Rajanikant GK (2012) Acceleration of wound repair by curcumin in the excision wound of mice exposed to different doses of fractionated γ radiation. Int Wound J 9(1):76–92CrossRefGoogle Scholar
  32. 32.
    Jiménez-Flores LM, Lopez-Briones S, Macías-Cervantes MH et al (2014) A PPARγ, NF-κB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver. Molecules 19(6):8289–8302CrossRefGoogle Scholar
  33. 33.
    Khan MA, Akhtar N, Sharma V et al (2015) Product development studies on sonocrystallized curcumin for the treatment of gastric cancer. Pharmaceutics 7(2):43–63CrossRefGoogle Scholar
  34. 34.
    Kundu P, Mohanty C, Sahoo S (2012) Antiglioma activity of curcumin loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater 8(7):2670–2687CrossRefGoogle Scholar
  35. 35.
    Lao CD, Ruffin MT 4th, Normolle D et al (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10CrossRefGoogle Scholar
  36. 36.
    Leclercq IA, Farrell GC, Sempoux C et al (2004) Curcumin inhibits NF-kappa B activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 41(6):926–934CrossRefGoogle Scholar
  37. 37.
    Li H, Zhang N, Hao Y et al (2014a) Formulation of curcumin delivery with functionalized single-walled carbon nanotubes: characteristics and anticancer effects in vitro. Drug Deliv 21(5):379–387CrossRefGoogle Scholar
  38. 38.
    Li X, Chen T, Xu L et al (2014b) Preparation of curcumin micelles and the in vitro and in vivo evaluation for cancer therapy. J Biomed Nanotechnol 10(8):1458–1468CrossRefGoogle Scholar
  39. 39.
    Li X, Yuan H, Zhang C et al (2016) Preparation and in-vitro/in-vivo evaluation of curcumin nanosuspension with solubility enhancement. J Pharm Pharmacol 68(8):980–988CrossRefGoogle Scholar
  40. 40.
    Liu L, Zhang P, Li Y et al (2012) Curcumin protects brain from oxidative stress through inducing expression of UCP2 in chronic cerebral hypo perfusion aging-rats. Mol Neurodegener 7:S10CrossRefGoogle Scholar
  41. 41.
    Liu Y, Cheng F, Luo Y (2017) PEGylated curcumin derivative attenuates hepatic steatosis via CREB/PPAR-γ/CD36 pathway. Biomed Res Int 2017:8234507PubMedPubMedCentralGoogle Scholar
  42. 42.
    Lopez-Jornet P, Camacho-Alonso F, Jimenez-Torres MJ et al (2011) Topical curcumin for the healing of carbon dioxide laser skin wounds in mice. Photomed Laser Surg 29(12):809–814CrossRefGoogle Scholar
  43. 43.
    Luer S, Troller R, Jetter M et al (2011) Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis? Support Care Cancer 19(6):799–806CrossRefGoogle Scholar
  44. 44.
    Madaric A, Kadrabova J, Krajcovicova-Kudlackova M et al (2013) The effect of bioactive complex of quercetin, selenium, catechins and curcumin on cardiovascular risk markers in healthy population after a two month consumption. Bratisl Lek Listy 114(2):84–87PubMedGoogle Scholar
  45. 45.
    Meng B, Li J, Cao H (2013) Antioxidant and anti-inflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des 19(11):2101–2113PubMedGoogle Scholar
  46. 46.
    Mutsuga M, Chambers JK, Uchida K et al (2012) Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer's brain. J Vet Med Sci 74(1):51–57CrossRefGoogle Scholar
  47. 47.
    Naksuriya O, Okonogi S, Schiffelers RM et al (2014) Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 35(10):3365–3383CrossRefGoogle Scholar
  48. 48.
    Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70(3):461–477CrossRefGoogle Scholar
  49. 49.
    Nonn L, Duong D, Peehl DM (2007) Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 28(6):1188–1196CrossRefGoogle Scholar
  50. 50.
    Pandit RS, Gaikwad SC, Agarkar GA (2015) Curcumin nanoparticles: physico-chemical fabrication and its in vitro efficacy against human pathogens. 3. Biotech 5(6):991–997Google Scholar
  51. 51.
    Park JH, Kim HA, Park JH et al (2012) Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs. Biomaterials 33(27):6542–6550CrossRefGoogle Scholar
  52. 52.
    Peng YM, Zheng JB, Zhou YB, Li J (2013) Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms. Acta pharmacol Sin 34(7):939–950CrossRefGoogle Scholar
  53. 53.
    Peng SF, Lee CY, Hour MJ (2014) Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human osteosarcoma cells through the Akt-Bad signaling pathway. Int J Oncol 44(1):238–246CrossRefGoogle Scholar
  54. 54.
    Prasad S, Tyagi AK, Aggarwal BB (2014) Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 46(1):2–18CrossRefGoogle Scholar
  55. 55.
    Priyadarsini KI (2014) The chemistry of curcumin: from extraction to therapeutic agent. Molecules 19(12):20091–20112CrossRefGoogle Scholar
  56. 56.
    Parimita SP, Ramshankar YV, Suresh S et al (2007) Redetermination of curcumin: (1E,4Z,6E)- 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy- phenyl)hepta-1,4,6- trien-3-one. Acta Cryst E63:860–862Google Scholar
  57. 57.
    Sari TP, Mann B, Kumar R et al (2015) Preparation and characterization of nanoemulsion encapsulating curcumin. Food Hydrocoll 43:540–546CrossRefGoogle Scholar
  58. 58.
    Shehzad A, Wahid F, Lee YS (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343(9):489–499CrossRefGoogle Scholar
  59. 59.
    Shehzad A, Lee J, Lee YS (2013) Curcumin in various cancers. Biofactors 39(1):56–68CrossRefGoogle Scholar
  60. 60.
    Shen JD, Wei Y, Li YJ et al (2017) Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. Metab Brain Dis 32(4):1163–1172CrossRefGoogle Scholar
  61. 61.
    Shoba G, Joy D, Joseph T et al (2007) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64(4):353–366CrossRefGoogle Scholar
  62. 62.
    Somparn P, Phisalaphong C, Nakornchai S (2007) Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 30(1):74–78CrossRefGoogle Scholar
  63. 63.
    Song SJ, Lee S, Ryu KS et al (2017) Amphiphilic peptide nanorods based on oligophenylalanine as a biocompatible drug carrier. Bioconjug Chem.  https://doi.org/10.1021/acs.bioconjchem.7b00247 CrossRefGoogle Scholar
  64. 64.
    Stanic Z (2017) Curcumin, a compound from natural sources, a true scientific challenge – a review. Plant Foods Hum Nutr 72(1):1–12CrossRefGoogle Scholar
  65. 65.
    Tian M, Wang L, Yu G et al (2012) Curcumin promotes cholesterol efflux from brain through LXR/RXR-ABCA1-apoA1 pathway in chronic cerebral hypoperfusion aging-rats. Mol Neurodegener 7(1):S7CrossRefGoogle Scholar
  66. 66.
    Tonnesen HH, Masson M, Loftsson T (2002) Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 244:127–135CrossRefGoogle Scholar
  67. 67.
    Van der Zanden LD, van Kleef E, de Wijk RA et al (2014) Knowledge, perceptions and preferences of elderly regarding protein-enriched functional food. Appetite 80:16–22CrossRefGoogle Scholar
  68. 68.
    Varemo L, Henriksen TI, Scheele C et al (2017) Type 2 diabetes and obesity induce similar transcriptional reprogramming in human myocytes. Genome Med 9(1):47CrossRefGoogle Scholar
  69. 69.
    Wang YJ, Pan MH, Cheng AL et al (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867–1876CrossRefGoogle Scholar
  70. 70.
    Wang P, Su C, Feng H et al (2017) Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice. Int J Immunopathol Pharmacol 30(1):25–43CrossRefGoogle Scholar
  71. 71.
    WHO technical report series-922 (2003) Evaluation of certain food additives and contaminants: sixty-first report of the Joint FAO/WHO Expert Committee on Food Additives, Rome, ItalyGoogle Scholar
  72. 72.
    Wongcharoen W, Phrommintikul A (2009) The protective role of curcumin in cardiovascular diseases. Int J Cardiol 133:145–151CrossRefGoogle Scholar
  73. 73.
    Yang X, Li Z, Wang N (2015) Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivo. Sci Rep 5:10322CrossRefGoogle Scholar
  74. 74.
    Yang KY, Lin LC, Tseng TY et al (2007) Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853:183–189CrossRefGoogle Scholar
  75. 75.
    Zaman MS, Chauhan N, Yallapu MM et al (2016) Curcumin nanoformulation for cervical cancer treatment. Sci Rep 6:20051CrossRefGoogle Scholar
  76. 76.
    Zhang DW, Fu M, Gao SH et al (2013) Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med 2013:636053PubMedPubMedCentralGoogle Scholar
  77. 77.
    Zhongfa L, Chiu M, Wang J et al (2012) Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 69(3):679–689CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of BiotechnologyJaypee Institute of Information TechnologyNoidaIndia

Personalised recommendations